Loading chat...
MO HB2643
Bill
Status
Introduced
1/7/2026
Primary Sponsor
Melanie Stinnett
Click for details
AI Summary
- Creates the "Hope for Missouri Patients Act" allowing patients with life-threatening or severely debilitating illnesses to access individualized investigational drugs, biological products, or devices based on their genetic profile
- Eligible patients must have considered all FDA-approved treatments, received a physician recommendation based on genomic analysis, and provided written informed consent
- Manufacturers operating within eligible facilities (those with Federalwide Assurance for Protection of Human Subjects) may provide individualized treatments and may charge patients for manufacturing costs
- Health plans, insurers, and government agencies are not required to cover costs of individualized investigational treatments or related services
- Protects health care providers from license revocation or Medicare certification action based solely on recommending individualized investigational treatment, and shields manufacturers from private lawsuits if they complied in good faith
Legislative Description
Establishes the "Hope for Missouri Patients Act"
Last Action
Reported Do Pass (H) - AYES: 12 NOES: 0 PRESENT: 0
3/16/2026
Committee Referrals
Emerging Issues2/12/2026
Full Bill Text
No bill text available